Smart Downstream Processing of Monoclonal Antibodies (mAbs)
Project Lead: Rensselaer Polytechnic Institute
Partners: Pennsylvania State University, Rensselaer Polytechnic Institute, Johnson & Johnson, Janssen Pharmaceuticals
Member % Cost Share: 50%
CESMII % Cost Share: 50%
Duration: 6 Months
Problem Statement
The common current or “platform” process for making monoclonal antibody-based drugs (mAbs) is insufficient to meet domestic or global pandemic needs. The Protein A chromatography capture step is the bottleneck.
Project Goal
Implement the CESMII SMIP for an alternative precipitation-based capture step to debottleneck process, focusing the precipitation and precipitate dewatering modules. The SMIP facilitates adoption of the new process by biomanufacturers.
Technical Approach
Instrument precipitation and dewatering modules; construct SM Profiles; create instances of SMIP connecting to edge device; create semi-empirical models for precipitate particle morphology and critical flux during dewatering; create process data dashboard; develop model-based feedback control of precipitation module; develop model-based feedforward control of dewatering module; demonstrate process operation under SMIP environment.
Deliverables/Outcomes/SM Marketplace
- Delivered Precipitate Morphology Model
- Delivered Critical Flux Model
- Precipitation Module SM profile
- Dewatering Module SM profile
- Precipitate Process Model
- Dewatering Process Model
Potential Impact
- Establish core of new debottlenecked mAb downstream process
- Meet FDA goal of fully continuous mAb downstream processing
- Control protein particle morphology: mAb ppts as well as virus-like particles, solid drug product phases
- Facilitate tech transfer and widespread adoption of new process using CESMII’s SMIP
Benefits
- Reusable and adaptable SM Profiles for precipitation and microfiltration
- Particle morphology and filtration critical flux prediction Apps in SM Marketplace
- Linkage between CESMII and NIIMBL
- Biotechnology industry use case example for SMIP and SM Profiles.
